Ultrasonography.  2017 Oct;36(4):370-377. 10.14366/usg.17015.

Ultrasound contrast-enhanced study as an imaging biomarker for anti-cancer drug treatment: preliminary study with paclitaxel in a xenograft mouse tumor model (secondary publication)

• Lee HJ
• Hwang SI
• Byun J
• Kong HY
• Jung HS
• Kang M

• KMID: 2393103
• DOI: http://doi.org/10.14366/usg.17015

Abstract

PURPOSE
The purpose of this study was to assess tumor angiogenesis using contrast-enhanced ultrasonography (CEUS) of human prostate cancer cells (PC3) that were implanted in mice before and after paclitaxel injection.
METHODS
Twelve mice were injected with human PC3. The mice were grouped into two groups; one was the paclitaxel-treated group (n=6) and the other was the control group (n=6). Before administering paclitaxel into the peritoneal cavity, baseline CEUS was performed after the administration of 500 μL (1×108 microbubbles) of contrast agent. The area under the curve (AUC) up to 50 seconds after injection was derived from the time-intensity curves. After injection of paclitaxel or saline, CEUS studies were performed at the 1-week follow-up. Changes in tumor volume and the AUC in both two groups were evaluated. After CEUS, the microvessel density (MVD) was compared between the groups.
RESULTS
In the paclitaxel-treated group, the AUC from CEUS showed a significant decrease 1-week after paclitaxel administration (P=0.030), even though the tumor volume showed no significant changes (P=0.116). In the control group, there was no significant decrease of the AUC (P=0.173). Pathologically, there was a significant difference in MVD between both groups (P=0.002).
CONCLUSION
The AUC from the time intensity curve derived from CEUS showed an early change in response to the anti-cancer drug treatment that preceded the change in tumor size. The findings of CEUS could serve as an imaging biomarker for assessing tumor responses to anti-cancer drug treatment.

Keyword

Ultrasonography; Contrast agent; Angiogenesis; Anti-cancer treatment; Animal study

MeSH Terms

Animals
Area Under Curve
Follow-Up Studies
Heterografts*
Humans
Mice*
Microvessels
Paclitaxel*
Peritoneal Cavity
Prostatic Neoplasms
Tumor Burden
Ultrasonography*
Paclitaxel